Drug Profile
JPH 211
Alternative Names: JPH 203-companion diagnostic agent - J-Pharma; JPH-211Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator J-Pharma
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Biliary cancer
- No development reported Solid tumours
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Solid-tumours(Diagnosis) in Japan
- 08 May 2020 Clinical trials are still ongoing for Cancer in Japan (J-Pharma pipeline, May 2020)
- 06 Nov 2018 Phase-II clinical trials in Biliary cancer (Diagnosis) in Japan (UMIN000034080)